Predictors of Carotid Occlusion Intolerance during Proximal Protected Carotid Artery Stenting

Original title: Predictors of Carotid Occlusion Intolerance During Proximal Protected Carotid Artery Stenting. Reference: Giuseppe Giugliano et al. J Am Coll Cardiol Intv 2014, Epub ahead of print.

Proximal endovascular occlusion devices (PEO) have been proved particularly effective and safe for proximal protected carotid stenting procedures. However, endovascular occlusion can expose the ipsilateral hemisphere to hypoperfusion and produce transient neurological symptoms.

Between March 2010 and 2012, 605 consecutive patients undergoing proximal protected carotid stenting in one center were included in this trial (Mo.Ma, Medtronic Inc., Santa Rosa, California). In order to identify independent predictors of carotid occlusion intolerance, multivariate logistic regression model was developed that included all clinical, angiographic and procedural characteristics of patients.

Compared to the asymptomatic subjects, those who presented intolerance had a lower occlusion pressure (42.3 ± 12.7 vs. 61.9 ± 15.4 mmHg; p< 0.001).

The most powerful independent predictor of proximal protection intolerance was occlusion pressure, with best cutoff being ≤40 mmHg (sensitivity 68.5%, specificity 93.3%). The best clinical predictor was the presence of collateral internal carotid artery occlusion (OR 3.1, IC 95% 1.5 a 6.2). 

Conclusion

Transient neurological symptoms can occur in one third of patients undergoing proximal protected carotid stenting. Contralateral Carotid occlusion and a ≤ 40 mmHg occlusion pressure are the best predictors.

Editorial Comment

Proximal occlusion intolerance has not been associated to peri procedural events and symptoms completely resolve within the first 20 minutes after flow restoration. Most of the times symptoms start after stenting (during post dilation or aspiration) therefore it is possible to finish procedure under protection. Only 1% of cases started with symptoms immediately after balloon inflation, in these cases the balloon may be deflated and the system may be used as a sheath guide filtered catheterization.

SOLACI

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...